Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797753 | 0.81 | DRD1 (0.49) | MEN1KMT2ARAB9AALDH1A1KDM4E | |
| SCHEMBL18059817 | 0.81 | KDM4E (0.39) | MEN1KMT2AAPAF1RAB9ASMN1; SMN2 | |
| SCHEMBL486670 | 0.80 | NR4A1 (0.61) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4799084 | 0.80 | TGFBR1 (0.45) | RAB9ASMN1; SMN2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL30072633 | 0.80 | TGFBR1 (0.45) | RAB9ASMN1; SMN2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8762387 | 0.78 | NR4A1 (0.58) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4328013 | 0.77 | NOS3 (0.55) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4794755 | 0.77 | NR4A1 (0.44) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9596150 | 0.77 | ALDH1A1 (0.57) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17242285 | 0.77 | P2RX3 (0.41) | MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-21 | — | — | US | disclosed |
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-20 | — | — | US | disclosed |
| US-20230097422-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | US | disclosed |
| CN-113121562-B | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | 詹森药业有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-08 | — | — | US | disclosed |
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-02 | — | — | US | disclosed |
| EP-3719022-A1 | POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE | Janssen Pharmaceutica NV (BE) | 2020-10-07 | — | — | EP | disclosed |
| US-10717745-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-21 | — | — | US | disclosed |
| EP-3386991-B1 | POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-03 | — | — | EP | disclosed |
| US-20190276471-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-12 | — | — | US | disclosed |
| EP-3386991-A1 | POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE | Janssen Pharmaceutica NV (BE) | 2018-10-17 | — | — | EP | disclosed |
| WO-2018103060-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | WO | disclosed |
| US-20170283430-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
| WO-2017100662-A1 | POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | MEN1 2524/4885KMT2A 2295/4885APAF1 1747/4885 |
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | MEN1 2524/4885KMT2A 2295/4885APAF1 1747/4885 |
| US-20170283430-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | MEN1 2524/4885KMT2A 2295/4885APAF1 1747/4885 |
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | MEN1 2475/4885KMT2A 2194/4885APAF1 1615/4885 |
| US-20230097422-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | MEN1 2524/4885KMT2A 2295/4885APAF1 1747/4885 |
| US-10717745-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | MEN1 2524/4885KMT2A 2295/4885APAF1 1747/4885 |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | MEN1 2475/4885KMT2A 2194/4885APAF1 1615/4885 |
| US-20190276471-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | MEN1 2524/4885KMT2A 2295/4885APAF1 1747/4885 |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | MEN1 2475/4885KMT2A 2194/4885APAF1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.